Biotechnology Assets (XMAD:BST) Total Receivables: €3.92 Mil (As of Dec. 2025)


XMAD:BST Biotechnology Assets SA XMAD:BST
22 GF Score
Price €0.23
GF Value €0.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biotechnology Assets Total Receivables?

Biotechnology Assets XMAD:BST -4.24% 22 Total Receivables is €3.92 Mil as of Dec. 2025. GuruFocus rates XMAD:BST with a GF Score™ of 22/100 and a GF Value™ of €0.30 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Biotechnology Assets's Total Receivables for the quarter that ended in Dec. 2025 was €3.92 Mil.

Biotechnology Assets Total Receivables Related Terms

Biotechnology Assets Total Receivables Historical Data

* Premium members only.

The historical data trend for Biotechnology Assets's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets Total Receivables Chart

Biotechnology Assets Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.64 2.31 3.34 3.43 3.92

Biotechnology Assets Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.34 2.19 3.43 2.54 3.92
XMAD:BST
22GF Score
Biotechnology Assets SA XMAD:BST
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotechnology Assets Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €3.92 Mil mean?
Biotechnology Assets (XMAD:BST) has a Total Receivables of €3.92 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Biotechnology Assets and its competitors.
Is Biotechnology Assets' Total Receivables too high?
Biotechnology Assets' current Total Receivables is €3.92 Mil. Overall, Biotechnology Assets has a GF Score™ of 22/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Total Receivables compare to VRTX and REGN?
Biotechnology Assets' Total Receivables of €3.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Total Receivables is €3.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.23 — trading 24.7% below its estimated fair value. The current Total Receivables is €3.92 Mil. Biotechnology Assets' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Total Receivables is €3.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.23 is trading 24.7% below its estimated GF Value™ of €0.30. GuruFocus considers Biotechnology Assets to be Modestly Undervalued.

Key valuation signals for XMAD:BST:

  • Total Receivables: €3.92 Mil
  • GF Value™: €0.30 vs. price of €0.23 (24.7% below fair value)
  • GF Score™: 22/100 with 3 warning signs

No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotechnology Assets Business Description

Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score

Get the complete analysis for XMAD:BST

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.30
GF Value